Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
205.48
-81.14 (-28.31%)
NASDAQ· Last Trade: Jul 30th, 9:40 PM EDT
Detailed Quote
Previous Close
286.62
Open
225.02
Bid
205.80
Ask
206.10
Day's Range
197.81 - 230.00
52 Week Range
197.81 - 495.55
Volume
9,839,944
Market Cap
24.42B
PE Ratio (TTM)
104.84
EPS (TTM)
2.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,926,174
Chart
About Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
Alnylam Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies using RNA interference (RNAi) technology to treat a range of genetic diseases. The company is dedicated to developing medicines that can selectively silence disease-causing genes, thereby addressing the underlying causes of conditions such as hereditary transthyretin-mediated amyloidosis and other rare disorders. With a strong commitment to research and development, Alnylam aims to deliver transformative treatments that improve patient outcomes and enhance quality of life for those affected by severe or life-threatening diseases. Read More
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported second-quarter 2026 global net product revenue of approximately $1.2 billion, up 74% from a year earlier, driven by continued uptake of AMVUTTRA for transthyretin amyloidosis with cardiomyopathy, or ATTR-CM.
Chief Executive Officer Yvonne Greenstreet s
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2026, and reviewed recent business highlights.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer’s Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases.
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 10 years by 3.79% on an annualized basis producing an average annual ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company’s pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company’s website at investors.alnylam.com/events, and a replay will be posted on the Alnylam website approximately three hours after each event.
Alnylam Pharmaceuticals (NASDAQ:ALNY) executives outlined the company’s 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst Salveen Richter.
Jeff Poulton, Alnylam’s chief financial officer, said the company’s “Alnylam 2030”
